Dupilumab 200 mg was efficacious in children (6-11 years) with moderate-to-severe asthma for up to 2 years: EXCURSION open-label extension study.

Wanda PhipatanakulChristian VogelbergLeonard B BacharierSharon DellArman AltincatalRebecca GallOliver LedanoisHarry SacksJuby A Jacob-NaraYamo DenizPaul J Rowe

Published in: Pediatric pulmonology (2024)

In children (6-11 years) with uncontrolled moderate-to-severe type 2 asthma, dupilumab 200 mg reduced exacerbation rates and improved lung function for up to 2 years and showed safety consistent with the known dupilumab safety profile.

Keyphrases

lung function
chronic obstructive pulmonary disease
atopic dermatitis
open label
young adults
cystic fibrosis
clinical trial
air pollution
high intensity
intensive care unit
study protocol